<DOC>
	<DOC>NCT02697591</DOC>
	<brief_summary>This is an open-label, non-randomized Phase 1/2 safety study of INCAGN01876 in subjects with advanced or metastatic solid tumors that will be conducted in 2 parts. Part 1 will determine the pharmacologically active dose and/or maximum tolerated dose of INCAGN01876. Part 2 will further evaluate the recommended dose determined in Part 1 in subjects with select tumor types.</brief_summary>
	<brief_title>An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent Part 1: Subjects with advanced or metastatic solid tumors Part 2: Subjects with advanced or metastatic adenocarcinoma of endometrium, melanoma, nonsmall cell lung cancer, and renal cell carcinoma Subjects who have disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or subjects who refuse standard treatment Presence of measureable disease based on RECIST v1.1 Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 Laboratory and medical history parameters not within the protocoldefined range Receipt of anticancer medications or investigational drugs within protocoldefined intervals before the first administration of study drug Has not recovered to â‰¤ Grade 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting therapy Receipt of a live vaccine within 30 days of planned start of study therapy Active autoimmune disease that required systemic treatment in the past 2 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>adenocarcinoma of the endometrium</keyword>
	<keyword>melanoma, non-small cell lung cancer (NSCLC)</keyword>
	<keyword>renal cell carcinoma (RCC)</keyword>
	<keyword>glucocorticoid-induced tumor necrosis factor receptor (GITR)</keyword>
</DOC>